GT201200228A - Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida - Google Patents

Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida

Info

Publication number
GT201200228A
GT201200228A GT201200228A GT201200228A GT201200228A GT 201200228 A GT201200228 A GT 201200228A GT 201200228 A GT201200228 A GT 201200228A GT 201200228 A GT201200228 A GT 201200228A GT 201200228 A GT201200228 A GT 201200228A
Authority
GT
Guatemala
Prior art keywords
methylpirrolidin
cyclohexylmetil
etil
tetrahydroisoquinolin
sulfonamide
Prior art date
Application number
GT201200228A
Other languages
English (en)
Inventor
Elenbaas Steven
Farr Robert Allan
Kane John Michael
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44012569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200228(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of GT201200228A publication Critical patent/GT201200228A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • C07C51/412Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A PROCEDIMIENTOS PARA PREPARAR 2-(CICLOHEXILMETIL)-N-{-[(2S)-1-METILPIRROLIDIN-2-IL]ETIL}-1,2,3,4-TETRAHIDROISOQUINOLIN-7-SULFONAMIDA, DIVERSOS COMPUESTOS INTERMEDIARIOS A LA MISMA Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LA MISMA, QUE SON LIGANDOS A LOS RECEPTORES DE HISTAMINA H3, QUE PUEDEN INFLUIR EN LA SECRECIÓN DE NEUROTRANSMISORES EN EL CEREBRO Y LA PERIFERIA Y SER ÚTIL EN EL TRATAMIENTO DE ENFERMEDAD DE ALZHEIMER Y OTRAS DEMENCIAS, OBESIDAD, TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL Y OTROS.
GT201200228A 2010-03-05 2012-07-20 Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida GT201200228A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106910P 2010-03-05 2010-03-05
FR1059750 2010-11-25

Publications (1)

Publication Number Publication Date
GT201200228A true GT201200228A (es) 2013-11-21

Family

ID=44012569

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200228A GT201200228A (es) 2010-03-05 2012-07-20 Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida

Country Status (27)

Country Link
US (2) US8748615B2 (es)
EP (2) EP2556064B1 (es)
JP (2) JP5927126B2 (es)
KR (2) KR101783679B1 (es)
CN (2) CN103221394A (es)
AR (2) AR080374A1 (es)
AU (2) AU2011223560A1 (es)
BR (2) BR112012022234A2 (es)
CA (2) CA2789669A1 (es)
CL (2) CL2012002451A1 (es)
CO (2) CO6630099A2 (es)
CR (1) CR20120467A (es)
DO (1) DOP2012000228A (es)
EC (1) ECSP12012207A (es)
GT (1) GT201200228A (es)
IL (2) IL221339A0 (es)
MA (2) MA34144B1 (es)
MX (2) MX2012008422A (es)
NZ (2) NZ601498A (es)
PE (1) PE20130007A1 (es)
RU (2) RU2012142338A (es)
SG (2) SG183256A1 (es)
TN (1) TN2012000361A1 (es)
TW (2) TW201144284A (es)
UY (2) UY33263A (es)
WO (2) WO2011109675A2 (es)
ZA (1) ZA201205311B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
CN102816101A (zh) * 2012-08-21 2012-12-12 江苏恒祥化工有限责任公司 一种(s)-n-甲基-2氯乙基吡咯烷的合成方法
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
KR20200061363A (ko) * 2017-10-04 2020-06-02 셀진 코포레이션 시스-4-[2-{[(3s,4r)-3-플루오로옥산-4-일]아미노}-8-(2,4,6-트리클로로아닐리노)-9h-퓨린-9-일]-1-메틸사이클로헥산-1-카르복스아미드의 제조 공정

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
GB8717374D0 (en) 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US4857301A (en) 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
WO1994029273A1 (en) 1993-06-09 1994-12-22 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
PL343424A1 (en) 1998-04-10 2001-08-13 Japan Tobacco Inc Amidine compounds
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
CA2347095A1 (en) 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogen-containing condensed heterocyclic derivatives, their production and agent
CA2366858A1 (en) 1999-04-01 2000-10-12 Margaret Yuhua Chu-Moyer Sorbitol dehydrogenase inhibitors
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
CN1215059C (zh) 1999-12-03 2005-08-17 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
FR2804429B1 (fr) 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2807434B1 (fr) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
AU2001296193B2 (en) 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
WO2002036560A1 (en) * 2000-10-30 2002-05-10 Warner-Lambert Company Llc Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
CA2450856A1 (en) * 2001-06-18 2002-12-27 Maruha Corporation Novel aliphatic compounds, their synthesis method, and utilization method of the same
JPWO2003011812A1 (ja) 2001-08-01 2004-11-18 持田製薬株式会社 ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
CA2469967A1 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
AU2004232939A1 (en) 2003-04-17 2004-11-04 Merck Sharp & Dohme Corp. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
FR2857695B1 (fr) 2003-07-15 2007-04-20 Saint Gobain Ct Recherches Bloc pour la filtration de particules contenues dans les gaz d'echappement d'un moteur a combustion interne
US20070117797A1 (en) 2004-01-02 2007-05-24 Goble Stephen D Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
US7410961B2 (en) 2004-01-20 2008-08-12 Merck & Co., Inc. 2,6-disubstituted piperiddines as modulators
CN1946696A (zh) 2004-04-26 2007-04-11 默克公司 四氢吡喃基环戊基1-取代的和1,1-二取代的四氢异喹啉趋化因子受体活性调节剂
CA2564499A1 (en) 2004-04-26 2005-12-22 Merck & Co., Inc. Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulators of chemokine receptor activity
GEP20084519B (en) 2004-05-11 2008-10-27 Incyte Corp 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
ES2257168B1 (es) 2004-08-18 2007-06-01 Laboratorios Del Dr Esteve, S.A. Ligandos del receptor 5-ht7.
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
CA2578441C (en) 2004-08-28 2013-01-08 Astrazeneca Ab Pyrimidine sulphonamide derivatives as chemokine receptor modulators
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
JP5132319B2 (ja) 2004-12-21 2013-01-30 スミスクライン ビーチャム コーポレーション 2−ピリミジニルピラゾロピリジンErbBキナーゼ阻害剤
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
RU2007126951A (ru) 2005-01-26 2009-03-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные фенилметанона и их применение в качестве ингибиторов переносчика глицина 1
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
RU2007145434A (ru) 2005-05-10 2009-06-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бициклические производные в качестве модуляторов ионных каналов
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
JP5443975B2 (ja) 2007-04-27 2014-03-19 富山化学工業株式会社 新規なスルホンアミド誘導体またはその塩
US20110071197A1 (en) 2008-04-16 2011-03-24 Peter Nilsson Bis-aryl compounds for use as medicaments
WO2010127272A2 (en) 2009-04-30 2010-11-04 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
WO2010151611A1 (en) 2009-06-26 2010-12-29 Sanofi-Aventis Novel fumarate salts of a histamine h3 receptor antagonist
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida

Also Published As

Publication number Publication date
IL221341A (en) 2014-05-28
JP5927126B2 (ja) 2016-05-25
AU2011223560A1 (en) 2012-09-13
RU2012142310A (ru) 2014-04-10
US8748615B2 (en) 2014-06-10
MA34144B1 (fr) 2013-04-03
AU2011222588B2 (en) 2016-09-08
EP2556064A2 (en) 2013-02-13
CO6630099A2 (es) 2013-03-01
TW201144285A (en) 2011-12-16
CN103068815A (zh) 2013-04-24
UY33263A (es) 2011-09-30
RU2012142338A (ru) 2014-04-10
KR20130047685A (ko) 2013-05-08
TN2012000361A1 (en) 2014-01-30
IL221341A0 (en) 2012-10-31
EP2542530A2 (en) 2013-01-09
NZ602009A (en) 2015-01-30
MX2012009413A (es) 2012-09-07
SG183256A1 (en) 2012-09-27
BR112012022356A2 (pt) 2016-08-30
TW201144284A (en) 2011-12-16
CO6630129A2 (es) 2013-03-01
IL221339A0 (en) 2012-10-31
WO2011109675A3 (en) 2012-11-22
CR20120467A (es) 2012-10-05
AR080375A1 (es) 2012-04-04
AU2011222588A1 (en) 2012-08-23
WO2011109675A2 (en) 2011-09-09
CN103221394A (zh) 2013-07-24
KR101783679B1 (ko) 2017-10-10
US8779145B2 (en) 2014-07-15
AR080374A1 (es) 2012-04-04
WO2011109680A2 (en) 2011-09-09
WO2011109680A3 (en) 2012-12-20
KR20130038186A (ko) 2013-04-17
PE20130007A1 (es) 2013-02-01
JP2013521309A (ja) 2013-06-10
CA2787427C (en) 2017-10-10
SG182576A1 (en) 2012-08-30
JP2013521308A (ja) 2013-06-10
BR112012022234A2 (pt) 2015-12-15
CL2012002451A1 (es) 2012-11-30
DOP2012000228A (es) 2013-01-15
US20130123302A1 (en) 2013-05-16
CA2787427A1 (en) 2011-09-09
CL2012002452A1 (es) 2012-11-30
MA34142B1 (fr) 2013-04-03
NZ601498A (en) 2014-12-24
UY33262A (es) 2011-09-30
EP2556064B1 (en) 2014-10-15
CA2789669A1 (en) 2011-09-09
ZA201205311B (en) 2013-03-27
US20130137718A1 (en) 2013-05-30
ECSP12012207A (es) 2013-03-28
MX2012008422A (es) 2012-08-15

Similar Documents

Publication Publication Date Title
CO6970607A2 (es) Moduladores del receptor mas acoplado a la proteína g y el tratamiento de trastornos relacionados con el mismo
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
CL2014002062A1 (es) Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros.
DOP2013000263A (es) Compuestos de 2- (2,4,5-anilino sustituido) pirimidina derivados como moduladores de egfr utilizados para el tratamiento del cáncer
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
CY1118021T1 (el) Παραγωγο αζολιου
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
CR11187A (es) Compuestos de quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6
CO2017001875A2 (es) Terapia de combinación contra el alzheimer usando anticuerpos anti-n3pglu más un inhibidor bace
EA201490569A1 (ru) Полиморфная форма гидрохлорида придопидина
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
DOP2012000174A (es) Metodo de tratamiento
GT201200228A (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
CR20150056A (es) Derivados de azaindol
GT201400242A (es) "nuevos compuestos de pirazol"
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201691160A1 (ru) Антагонисты s1p3
AR096165A1 (es) Síntesis de 3-(5-amino-2-metil-4-oxoquinazolin-3(4h)-il)piperidin-2,6-diona
BR112017000584A2 (pt) inibidores da aldosterona sintase
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
PE20121403A1 (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
BR112014024736A2 (pt) antagonista receptor de h3 para uso no tratamento de doença de alzheimer
BR112016016098A2 (pt) Compostos orgânicos